Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: Semaglutide
Drug: SNAC
Drug: Levothyroxine
Drug: Placebo

First Posted Date: 2016-09-30

Last Posted Date: 2017-12-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT02920385

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Phase 3

Completed

Conditions: Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: Placebo
Drug: Liraglutide

First Posted Date: 2016-09-28

Last Posted Date: 2020-04-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 251

Registration Number: NCT02918279

Locations: 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide
Drug: Insulin degludec

First Posted Date: 2016-09-23

Last Posted Date: 2021-04-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 210

Registration Number: NCT02911948

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yamaguchi-shi, Yamaguchi, Japan

A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SNAC
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2016-09-22

Last Posted Date: 2018-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT02911870

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2016-09-20

Last Posted Date: 2022-07-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 703

Registration Number: NCT02906930

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/insulin aspart
Drug: Insulin glargine
Drug: Insulin aspart

First Posted Date: 2016-09-20

Last Posted Date: 2019-11-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 532

Registration Number: NCT02906917

Locations: 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide

First Posted Date: 2016-08-24

Last Posted Date: 2019-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 55

Registration Number: NCT02877355

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: NNC9204-0530
Drug: liraglutide
Drug: placebo

First Posted Date: 2016-08-17

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 187

Registration Number: NCT02870231

Locations: 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Phase 1

Completed

Conditions: Anemia

Interventions: Drug: COR-001
Other: Placebo

First Posted Date: 2016-08-16

Last Posted Date: 2021-07-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 61

Registration Number: NCT02868229

Locations: 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide
Drug: liraglutide

First Posted Date: 2016-08-11

Last Posted Date: 2022-07-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 711

Registration Number: NCT02863419

Locations: 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy